Amuvatinib

Other name

DB12742

International/Other brands

Amuvatinib hydrochloride

Groups

Investigational

Structure

Prescription products

Target

KIT, MET

Description

Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.

Indications

-

Other indications

-

Mechaism of action

-

Absorption

-

Metabolism

-

Toxicity

-